Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 1, 2019
Daily News
November 1, 2019
- Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
- Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Key Japan Panel OKs Xolair as 1st Antibody Drug for Pollen Allergy
November 1, 2019
- Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
- Astellas, Pandion Link Arms on Pancreas-Targeted Immunomodulators
November 1, 2019
- Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Satralizumab Accepted for Review in Europe, US; Chugai Plans Japan Filing Before Year-End
November 1, 2019
- Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…